Twist Bioscience Corp (0ME.SG)
| Previous close | 52.48 |
| Open | 53.10 |
| Bid | 53.02 x 280000 |
| Ask | 53.64 x 190000 |
| Day's range | 53.10 - 53.10 |
| 52-week range | 13.96 - 54.10 |
| Volume | |
| Avg. volume | 53 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksTwist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWant Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Business WireTwist Bioscience Announces Clinical Progression of Pure Biologics’ Antibody Candidate Discovered Using Twist’s Antibody Libraries
SOUTH SAN FRANCISCO, Calif., July 18, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the first patient has been dosed in Pure Biologics’ exploratory Phase 0 clinical study of PBA-0405. PBA-0405 is a fully human IgG1 antibody that was discovered using Twist Biopharma Solutions’ synthetic antibody phage display libraries. Twist Biopharma Solutions, a divis
